Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Myfortic for the treatment of bullous pemphigoid: open-label monocentric proof-of-concept study
2005-001827-12Phase 2Completed
- Sponsor
- Universitätsmedizin Göttingen
- Start
- Jul 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mycophenolate sodium in Bullous Pemphigoid (BP), sponsored by Universitätsmedizin Göttingen. Primary endpoint: Change in clinical activity parameters of bullous pemphigoid. Started Jul 2005; status: completed.
02
Drugs
mycophenolate sodium
03
Conditions
Bullous Pemphigoid (BP)
Beyond the preview
Go deeper on 2005-001827-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001827-12.